Frequent egfr and ntrk somatic mutations in colorectal cancer (crc) with microsatellite instability (msi)
AssigneeInstitute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
InventorsSafoora Deihimi, Michael Slifker, Wafik S. El-Deiry
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for identifying subjects having a cancer or tumor that may be susceptible to treatment with a therapeutic agent used to EGFR-related cancer an/or NTRK-related cancer.
Claims15
1-16. (canceled).
A method for treating cancer or tumor having high microsatellite instability in a subject, wherein the subject is diagnosed with a cancer or tumor having high microsatellite instability if the one or more mutations in EGFR and/or NTRK are detected, comprising:
- performing immunohistochemistry, sequencing, and/or microsatellite instability analysis on a sample obtained from the subject to identify a high microsatellite instability;
- detecting one or more mutations in EGFR and/or NTRK;
- wherein the subject is diagnosed with a cancer or tumor having high microsatellite instability if the one or more mutations in EGFR and/or NTRK are detected;
- and
- administering a therapeutic agent to the subject having one or more mutations in EGFR and/or NTRK, wherein the therapeutic agent is an agent used to treat EGFR-related cancer and/or NTRK-related cancer.
22-29. (canceled).
A method for identifying a subject having a cancer or tumor that may be susceptible to treatment with a therapeutic agent used to treat EGFR-related cancer or NTRK-related cancer, comprising:
- analyzing a sample from the subject for the presence or absence of one or more mutations in EGFR and/or NTRK;
- wherein the subject is diagnosed with the cancer or tumor having high microsatellite instability related to one or more mutations in EGFR and/or NTRK, wherein the subject may be susceptible to treatment with a therapeutic agent used to treat EGFR-related cancer or NTRK-related cancer.
Dependencies are inferred from the claim text.